Inhibition of Coxsackievirus-Associated dystrophin cleavage prevents cardiomyopathy

Journal of Clinical Investigation

Volumn 123, Issue 12, 2013, Pages 5146-5151

  Lim, Byung Kwan ^a,b   Peter, Angela K ^a   Xiong, Dingding ^c   Narezkina, Anna ^a   Yung, Aaron ^d   Dalton, Nancy D ^a   Hwang, Kyung Kuk ^e   Yajima, Toshitaka ^a   Chen, Ju ^a   Knowlton, Kirk U ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Jungwon University   (South Korea)

^c MEDICAL COLLEGE OF OHIO   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e Chungbuk National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; PROTEIN VP1; PROTEINASE; PROTEINASE 2A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; COXSACKIE VIRUS INFECTION; CYTOPATHOGENIC EFFECT; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; HEART MUSCLE CELL; HUMAN; HUMAN CELL; M MODE ECHOCARDIOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SARCOLEMMA; TRANSGENE; VIRUS REPLICATION; VIRUS TITRATION; WILD TYPE;

ANIMALS; CELLS, CULTURED; COXSACKIEVIRUS INFECTIONS; CYSTEINE ENDOPEPTIDASES; CYTOPATHOGENIC EFFECT, VIRAL; DYSTROPHIN; ENTEROVIRUS B, HUMAN; GENE KNOCK-IN TECHNIQUES; MALE; MICE; MICE, INBRED C3H; MUTATION; MYOCARDITIS; MYOCYTES, CARDIAC; PROTEOLYSIS; RECOMBINANT FUSION PROTEINS; SARCOLEMMA; TRANSGENES; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84890057058     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI66271     Document Type: Article

References (19)

1. Badorff C, et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med. 1999;5(3):320-326
2. Gradi A, et al. A novel functional human eukaryotic translation initiation factor 4G. Mol Cell Biol. 1998; 18(1):334-342
3. Lamphear BJ, et al. Mapping the cleavage site in protein synthesis initiation factor eIF-4 gamma of the 2A proteases from human Coxsackievirus and rhinovirus. J Biol Chem. 1993;268(26):19200-19203
4. Castello A, Alvarez E, Carrasco L. Differential cleavage of eIF4GI and eIF4GII in mammalian cells. Effects on translation. J Biol Chem. 2006; 281(44):33206-33216
5. Xiong D, et al. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Nat Med. 2002;8(8):872-877
6. Mavrogeni S, et al. Myocardial inflammation in Duchenne Muscular Dystrophy as a precipitating factor for heart failure: a prospective study. BMC Neurol. 2010;10:33
7. Xiong D, et al. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation. 2007; 115(1):94-102
8. Badorff C, Berkely N, Mehrotra S, Talhouk JW, Rhoads RE, Knowlton KU. Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin- based substrate analogue. J Biol Chem. 2000; 275(15):11191-11197
9. Bodensteiner JB, Engel AG. Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: a study of 567,000 muscle fibers in 114 biopsies. Neurology. 1978;28(5):439-446
10. Nakayama H, et al. Ca2+- and mitochondrialdependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest. 2007; 117(9):2431-2444
11. Konno T, et al. Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A. 2010;107(42):18097-18102
12. Lapidos KA, Kakkar R, McNally EM. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res. 2004; 94(8):1023-1031
13. Lee GH, Badorff C, Knowlton KU. Dissociation of sarcoglycans and the dystrophin carboxyl terminus from the sarcolemma in enteroviral cardiomyopathy. Circ Res. 2000;87(6):489-495
14. Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, Sanes Jr. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell. 1997;90(4):729-738
15. Celes MR, et al. Disruption of sarcolemmal dystrophin and beta-dystroglycan may be a potential mechanism for myocardial dysfunction in severe sepsis. Lab Invest. 2010;90(4):531-542
16. Wang J, et al. Cardiomyopathy associated with microcirculation dysfunction in laminin alpha4 chaindeficient mice. J Biol Chem. 2006;281(1):213-220
17. Barresi R, et al. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations. J Med Genet. 2000; 37(2):102-107
18. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919-928
19. Lim BK, et al. Coxsackievirus and adenovirus receptor (CAR) mediates atrioventricular-node function and connexin 45 localization in the murine heart. J Clin Invest. 2008;118(8):2758-2770